With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

目前，强生正在加速拓展古塞奇尤单抗的适应症范围，2025 年预计将有 6 个新适应症获批上市，包括溃疡性结肠炎（皮下诱导）、克罗恩病（皮下诱导）、儿童银屑病、克罗恩病、幼年型银屑病关节炎、溃疡性结肠炎，意味着未来有望进入加速放量期。

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

IXIFI is a biosimilar to Remicade (infliximab). It was approved by Health Canada in December 2021 for all eligible indications of the reference product.

Treatment for microscopic colitis usually involves medication to reduce symptoms. Learn about medication types and other ...

Celltrion’s strategy with its biosimilar of MSD’s Remicade (infliximab), launched in most of Europe around two years ago, was to go for two marketing authorisations and sell rights to one of ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...